ACE2 and COVID-19: The risk of ICH in COVID-19 positive patients might be further enhanced due to pathophysiological mechanisms associated with COVID-19 including dysfunction of the renin-angiotensin system leading to reduced ACE2 expression, hypertension, elevated D-dimer and tPA plasma levels, as well as cerebral endothelial dysfunction caused by inflammatory factors (25, 31).